|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | The Hospital for Sick Children |
|---|---|
| Collaborators: |
National Center for Research Resources (NCRR) GlaxoSmithKline Children's Memorial Hospital |
| Information provided by: | The Hospital for Sick Children |
| ClinicalTrials.gov Identifier: | NCT00120744 |
Purpose
The objectives of the study were to determine whether ondansetron treatment would reduce:
| Condition | Intervention |
|---|---|
|
Gastroenteritis Vomiting Diarrhea Dehydration |
Drug: Ondansetron Oral Disintegrating Tablet |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Randomized Trial of the Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Acute Gastroenteritis in a Pediatric Emergency Department |
| Study Start Date: | January 2004 |
| Estimated Study Completion Date: | April 2005 |
Background:
Vomiting may limit the success of oral rehydration in children with gastroenteritis and dehydration. Limited data suggest that while oral ondansetron may reduce vomiting from gastroenteritis, emergency department revisits may increase.
Methods:
The investigators conducted a prospective, double-blind randomized trial at a pediatric emergency department in 214 dehydrated children, aged 6 months to 10 years with gastroenteritis and mild to moderate dehydration as assessed by a dehydration score. They were randomly assigned to receive treatment with an ondansetron oral disintegrating tablet or placebo. Oral rehydration was administered according to a standard protocol. The primary outcome was the proportion of children who vomited during oral rehydration therapy. The secondary outcomes were the mean number of episodes of vomiting, and the proportion of children treated with intravenous rehydration or hospitalized.
Eligibility| Ages Eligible for Study: | 6 Months to 10 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | 2003-12038 |
| Study First Received: | July 12, 2005 |
| Last Updated: | September 7, 2006 |
| ClinicalTrials.gov Identifier: | NCT00120744 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Neurotransmitter Agents Disease Attributes Vomiting Molecular Mechanisms of Pharmacological Action Signs and Symptoms, Digestive Gastrointestinal Diseases Physiological Effects of Drugs Psychotropic Drugs Antiemetics Signs and Symptoms Serotonin Antagonists Pathologic Processes Therapeutic Uses Antipruritics Water-Electrolyte Imbalance |
Ondansetron Dermatologic Agents Tranquilizing Agents Metabolic Diseases Diarrhea Gastrointestinal Agents Central Nervous System Depressants Antipsychotic Agents Pharmacologic Actions Serotonin Agents Digestive System Diseases Autonomic Agents Emergencies Anti-Anxiety Agents Peripheral Nervous System Agents |